Website

www.teddyoung.org

Role of CVBF

Coordinator

Description

The TEDDY Network of Excellence was created under the Sixth Framework Programme for Research and Technological Development, FP6, with the goal to support and strengthen scientific and technological excellence in the paediatric sector in Europe.

At the end of the funding period, the Task-force was further renewed and now TEDDY is operating as an independent multidisciplinary, multinational network including 28 centres in 15 EU and non EU-countries. The aim of this new network is to encourage the integration of the paediatric pharmacological research activities, the implementation of adequate health policies and the promotion of social awareness on the importance of the paediatric medicines across Europe. Indeed, among its partners the TEDDY network includes paediatric clinical research centres as well as professionals (methodologists, pharmacologists, ethicists, regulators) with extensive expertise in the paediatric sector. Researchers, scientists, health experts are still working together to identify the most appropriate common rules that reflect the specificity of this patient population. TEDDY offers its experience in the planning and management of clinical trials in the paediatric field and operates as a support network for the recruitment of patients.

Funds

Sixth Framework Programme, European Commission

EU Contribution

4.4 million euro

Duration

2005-2010

Partners

(1) Consorzio per le Valutazioni Biologiche e Farmacologiche, Italy; (2) Azienda Ospedaliera di Padova, Italy; (3) University College London, UK; (4) Rijksuniversiteit Leiden,  The Netherlands; (5) Consiglio Nazionale delle Ricerche – Istituto di Tecnologie Biomediche, Italy; (6) Erasmus University Medical Center, The Netherlands; (7) Istituto Superiore di Sanità, Italy; (8) Romanian Angel Appeal, Romania; (9) Linköpings Universitet, Sweden ; (10) Institut National de la Sante et Recherche Medicale, France; (11) Medical Research Council – Clinical Trials Unit, UK; (12) Hospital Carlos III, Spagna; (13) Universite de Liege, Belgium; (14) Institute of Physiology, Academy of Sciences, Lab. of Neurophysiology of Memory, Czech Republic; (15) Technion – Israel Institute of Technology, Israele; (16) Charité – Universitätsmedizin Berlin, Germany; (17) Tecnofarmaci – Società Consortile per Azioni – per lo Sviluppo della Ricerca Farmaceutica, Italy; (18) IRIDIA Srl, Italia; (19) School of Pharmacy, UK.